CL2016001001A1 - Profármacos y moduladores de receptores nmda, sales y usos de estos - Google Patents
Profármacos y moduladores de receptores nmda, sales y usos de estosInfo
- Publication number
- CL2016001001A1 CL2016001001A1 CL2016001001A CL2016001001A CL2016001001A1 CL 2016001001 A1 CL2016001001 A1 CL 2016001001A1 CL 2016001001 A CL2016001001 A CL 2016001001A CL 2016001001 A CL2016001001 A CL 2016001001A CL 2016001001 A1 CL2016001001 A1 CL 2016001001A1
- Authority
- CL
- Chile
- Prior art keywords
- modulators
- prodrugs
- salts
- nmda receptors
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPUESTOS MACROCICLICOS DERIVADOS DE PEPTIDILO SUSTITUIDOS, MODULADORES DEL RECEPTOR NMDA; COMPOSICION FARMACEUTICA; Y SU USO PARA TRATAR AUTISMO, DEPRESION, EPILEPSIA, DEMENCIA ASOCIADA AL SIDA, ATROFIA MULTISITEMICA, PARALISIS SUPRANUCLEAR PROGRESIVA, ATAXIA DE FRIEDRICH, SINDROME DE DOWN, SINDROME X FRAGIL, ENTRE OTROS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361896308P | 2013-10-28 | 2013-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016001001A1 true CL2016001001A1 (es) | 2016-12-16 |
Family
ID=53004986
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001001A CL2016001001A1 (es) | 2013-10-28 | 2016-04-27 | Profármacos y moduladores de receptores nmda, sales y usos de estos |
CL2020002247A CL2020002247A1 (es) | 2013-10-28 | 2020-08-31 | Compuestos macrociclicos derivados de peptidilo sustituidos (divisional de solicitud n° 01001-2016) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002247A CL2020002247A1 (es) | 2013-10-28 | 2020-08-31 | Compuestos macrociclicos derivados de peptidilo sustituidos (divisional de solicitud n° 01001-2016) |
Country Status (15)
Country | Link |
---|---|
US (2) | US9745342B2 (es) |
EP (2) | EP3564256A1 (es) |
JP (1) | JP6603668B2 (es) |
KR (1) | KR20160077153A (es) |
CN (2) | CN112321678A (es) |
AU (2) | AU2014342624A1 (es) |
BR (1) | BR112016009443A8 (es) |
CA (1) | CA2928701A1 (es) |
CL (2) | CL2016001001A1 (es) |
IL (1) | IL245302B (es) |
MX (2) | MX2016005510A (es) |
RU (1) | RU2016119830A (es) |
SA (1) | SA516371037B1 (es) |
SG (2) | SG10201810496XA (es) |
WO (1) | WO2015065891A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2948140T3 (en) | 2013-01-22 | 2017-08-21 | Vistagen Therapeutics Inc | DOSAGE FORMS AND THERAPEUTIC APPLICATIONS OF L-4-CHLORCYNURENINE |
CN116082461B (zh) * | 2022-10-14 | 2023-11-14 | 浙江大学 | 一种具有抗菌活性的小分子肽及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1801118A4 (en) | 2004-09-14 | 2009-09-02 | Shionogi & Co | METHOD FOR SYNTHESIS OF MUCIN-TYPE PEPTIDES AND GLUCKOPEPTIDES RELATED TO MUC1 |
EP2094721B1 (en) * | 2006-12-14 | 2018-02-14 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
ES2648687T3 (es) * | 2007-02-23 | 2018-01-05 | Aileron Therapeutics, Inc. | Péptidos macrocíclicos unidos a triazol |
EP2331571B1 (en) * | 2008-09-18 | 2015-08-26 | Northwestern University | Nmda receptor modulators and uses thereof |
CN104961795A (zh) * | 2008-09-22 | 2015-10-07 | 爱勒让治疗公司 | 用于制备纯化的多肽组合物的方法 |
SG10201811584RA (en) * | 2010-02-11 | 2019-01-30 | Univ Northwestern | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
SG10202010665YA (en) * | 2011-04-27 | 2020-11-27 | Univ Northwestern | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
-
2014
- 2014-10-27 US US15/033,031 patent/US9745342B2/en active Active
- 2014-10-27 CN CN202010688442.5A patent/CN112321678A/zh active Pending
- 2014-10-27 EP EP19159957.0A patent/EP3564256A1/en not_active Withdrawn
- 2014-10-27 CA CA2928701A patent/CA2928701A1/en not_active Abandoned
- 2014-10-27 RU RU2016119830A patent/RU2016119830A/ru unknown
- 2014-10-27 EP EP14858298.4A patent/EP3062810A4/en not_active Withdrawn
- 2014-10-27 JP JP2016552196A patent/JP6603668B2/ja not_active Expired - Fee Related
- 2014-10-27 AU AU2014342624A patent/AU2014342624A1/en not_active Abandoned
- 2014-10-27 SG SG10201810496XA patent/SG10201810496XA/en unknown
- 2014-10-27 BR BR112016009443A patent/BR112016009443A8/pt not_active IP Right Cessation
- 2014-10-27 KR KR1020167013971A patent/KR20160077153A/ko not_active Application Discontinuation
- 2014-10-27 MX MX2016005510A patent/MX2016005510A/es unknown
- 2014-10-27 SG SG11201603376UA patent/SG11201603376UA/en unknown
- 2014-10-27 WO PCT/US2014/062367 patent/WO2015065891A1/en active Application Filing
- 2014-10-27 CN CN201480064349.XA patent/CN105764522A/zh active Pending
-
2016
- 2016-04-25 IL IL245302A patent/IL245302B/en active IP Right Grant
- 2016-04-27 MX MX2021000029A patent/MX2021000029A/es unknown
- 2016-04-27 CL CL2016001001A patent/CL2016001001A1/es unknown
- 2016-04-28 SA SA516371037A patent/SA516371037B1/ar unknown
-
2017
- 2017-07-24 US US15/658,107 patent/US10590167B2/en not_active Expired - Fee Related
-
2020
- 2020-02-17 AU AU2020201109A patent/AU2020201109A1/en not_active Abandoned
- 2020-08-31 CL CL2020002247A patent/CL2020002247A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US10590167B2 (en) | 2020-03-17 |
SA516371037B1 (ar) | 2018-05-16 |
JP2016537413A (ja) | 2016-12-01 |
EP3062810A4 (en) | 2017-05-03 |
CN112321678A (zh) | 2021-02-05 |
CN105764522A (zh) | 2016-07-13 |
WO2015065891A1 (en) | 2015-05-07 |
MX2016005510A (es) | 2017-01-06 |
EP3062810A1 (en) | 2016-09-07 |
US9745342B2 (en) | 2017-08-29 |
US20180127466A1 (en) | 2018-05-10 |
CA2928701A1 (en) | 2015-05-07 |
RU2016119830A3 (es) | 2018-07-02 |
BR112016009443A8 (pt) | 2020-03-24 |
SG11201603376UA (en) | 2016-05-30 |
AU2020201109A1 (en) | 2020-03-05 |
SG10201810496XA (en) | 2018-12-28 |
RU2016119830A (ru) | 2017-12-04 |
AU2014342624A1 (en) | 2016-06-02 |
IL245302A0 (en) | 2016-06-30 |
KR20160077153A (ko) | 2016-07-01 |
CL2020002247A1 (es) | 2021-02-05 |
EP3564256A1 (en) | 2019-11-06 |
IL245302B (en) | 2020-05-31 |
MX2021000029A (es) | 2021-03-25 |
US20160244485A1 (en) | 2016-08-25 |
JP6603668B2 (ja) | 2019-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
CL2023001911A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
CL2018000883A1 (es) | Moduladores del receptor x farnesoide | |
EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
CL2018000819A1 (es) | Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso | |
GT201500093A (es) | Moduladores de quinolinilo unidos a metileno de ror- gamma-t | |
CL2016001415A1 (es) | Composiciones farmacéuticas que comprenden fumarato de dimetilo | |
CL2015002655A1 (es) | Moduladores de p2x7 | |
CO7151531A2 (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
DOP2015000058A (es) | Derivados tricíclicos de quinolinas y de quinoxalinas | |
CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
BR112014020826A2 (pt) | moduladores e métodos de uso | |
PH12016500374A1 (en) | Biaryl acetamide compounds and methods of use thereof | |
EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
CL2015002121A1 (es) | Modulares de receptores nmda de espiro-lactama y sus usos. | |
UY33917A (es) | ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?. | |
UY34832A (es) | TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda) | |
CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
BR112016004245A2 (pt) | moduladores de sez6 e métodos de uso | |
CL2017000716A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos | |
CL2017003124A1 (es) | Moduladores alostéricos positivos del receptor de m2 muscarínico | |
MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). |